# Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

> **NCT00026143** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IV Melanoma

## Interventions

- **BIOLOGICAL:** recombinant interleukin-12
- **BIOLOGICAL:** recombinant interferon alfa
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00026143
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2004-07
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00026143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00026143, "Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00026143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*